Nicotinic acetylcholine receptors (nAChRs) have been historically defined as ligand-gated
ion channels and function as such in the central and peripheral nervous systems. Recently …

There have been numerous attempts to develop non-opioid drugs for severe pain, but the
vast majority of these efforts have failed. A notable exception is Ziconotide (Prialt®) …

Opioids are first-line drugs for moderate to severe acute pain and cancer pain. However,
these medications are associated with severe side effects, and whether they are efficacious …

Nicotinic acetylcholine receptors (nAChRs) are actively being investigated as therapeutic
targets for the treatment of pain and inflammation, but despite more than 30 years of …

Nicotinic acetylcholine receptors (nAChRs) present as many different subtypes in the
nervous and immune systems, muscles and on the cells of other organs. In the immune …

Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs),
therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available …

We discuss models for the activation and desensitization of α7 nicotinic acetylcholine
receptors (nAChRs) and the effects of efficacious type II positive allosteric modulators …

We identified a previously unidentified conotoxin gene from Conus generalis whose
precursor signal sequence has high similarity to the O1-gene conotoxin superfamily. The …

Chemotherapy-induced neuropathic pain is a debilitating and dose-limiting side effect.
Oxaliplatin is a third-generation platinum and antineoplastic compound that is commonly …

Abstract α-Conotoxins are disulfide-rich and well-structured peptides, most of which can
block nicotinic acetylcholine receptors (nAChRs) with exquisite selectivity and potency …